Stock events for Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics' stock price has experienced significant volatility. The share price was $4.26 as of March 5, 2026, representing a 65.12% increase over the past year but down 17.74% in the last six months. Key events impacting the stock include FDA deficiencies and a Complete Response Letter for Anaphylm, a larger-than-expected loss for Q4 2025, increased SG&A expenses, and analyst downgrades.
Demand Seasonality affecting Aquestive Therapeutics, Inc.’s stock price
Information regarding demand seasonality for most of Aquestive Therapeutics' products is not explicitly detailed. However, there is an indication of potential seasonality for Anaphylm, with commercialization efforts expected to ramp up ahead of the peak spring allergy season. Suboxone Sublingual Film has reported consistent order demand.
Overview of Aquestive Therapeutics, Inc.’s business
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative medicines using its proprietary drug delivery technologies, particularly PharmFilm. The company's product portfolio includes commercialized products like Suboxone Sublingual Film, Sympazan Oral Film, Ondif Oral Film, Azstarys, KYNMOBI Sublingual Film, and Exservan Oral Film. Its proprietary pipeline features product candidates such as Anaphylm Sublingual Film, Libervant Buccal Film, and AQST-108.
AQST’s Geographic footprint
Aquestive Therapeutics is headquartered in Warren, New Jersey, USA, and operates both in the United States and internationally. The majority of its revenue is generated from the United States.
AQST Corporate Image Assessment
Aquestive Therapeutics' brand reputation has been negatively impacted by regulatory setbacks and associated legal actions. The FDA's deficiencies and Complete Response Letter for Anaphylm have raised concerns. A class-action lawsuit alleging that the company misled investors regarding Anaphylm's approval has further damaged the company's brand reputation and investor confidence.
Ownership
Aquestive Therapeutics has a diverse ownership structure. Institutional shareholders hold approximately 59.17% of the stock, individual retail investors hold around 34.59%, and insiders own about 6.24% of the company. Bratton Capital Management, L.P. is the largest single institutional holder. Douglas K. Bratton is the largest individual shareholder.
